SQZ Biotechnologies CoOver The Counter Market:SQZB
- LAST PRICE0.0465
- TODAY'S CHANGE (%)0.0000 (0.0000%)
- Bid / Lots---/ ---
- Ask / Lots---/ ---
- Open / Previous Close0.0000 / 0.0465
- Day Range---
- 52 Week Range
- Volume---
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
SQZ Biotechnologies Co | 1.4M | 0.0x | --- |
Agile Therapeutics Inc | 2.7M | 0.0x | --- |
Predictive Technology Group Inc | 149.8K | 0.0x | --- |
Emmaus Life Sciences Inc | 5.4M | -1.1x | --- |
Viaderma Inc | 12.3M | 0.0x | --- |
Response Genetics Inc | 40.0 | 0.0x | --- |
Company Information
SQZ Biotechnologies Company is a clinical-stage biotechnology company. The Company is focused on unlocking the full potential of cell therapies to benefit patients. In oncology, it is developing cell therapy platforms that are based on directing tumor antigen-specific immune activation via engineered antigen presentation. Its clinical-stage cell therapy candidates include SQZ Enhanced APC (eAPC) Platform, SQZ Activating Antigen Carrier (AAC) Platform and SQZ Tolerizing Antigen Carrier (TAC) Platform. The SQZ eAPC platform is the second-generation product candidate designed to generate tumor specific CD8+ T cell activation to drive the antitumor immune response. The SQZ AAC platform is designed to induce antigen presentation in vivo by deriving antigen carriers from engineering red blood cells (RBCs) with tumor specific antigens and adjuvants. Its SQZ TAC platform is designed to induce antigen-specific immune tolerance in vivo by utilizing a similar approach to the AAC platform.
Contact Information
- Headquarters
- 200 Arsenal Yards Blvd, Suite 210WATERTOWN, MA, United States 02472
- Phone
- 617-758-8672
- Fax
- 302-655-5049
Executives
- Independent Non-Executive Chairman of the Board
- Bernard Coulie
- Director
- Howard Bernstein
- Chief People Officer
- David First
- Chief Accounting Officer
- Richard Capasso
- General Counsel
- Lawrence Knopf
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $1.4M |
|---|---|
Revenue (TTM) | $12.1M |
Shares Outstanding | 29.5M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.46 |
EPS | $-2.43 |
Book Value | $1.94 |
P/E Ratio | 0.0x |
Price/Sales (TTM) | 0.1 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -603.85% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
